#United States #New York #Class Action #Wolf Haldenstein #Aardvark Therapeutics

Wolf Haldenstein Advocates for Aardvark Shareholders

In a significant legal move, Wolf Haldenstein Adler Freeman & Herz LLP, a well-respected firm in securities litigation, has issued a call to action for shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD) who may have incurred financial losses. The firm has filed a securities class action lawsuit on behalf of those who purchased Aardvark shares, specifically during the period of its Initial Public Offering (IPO) that took place around February 13, 2025, and up until May 14, 2026.

Details of the Lawsuit

The lawsuit, filed in the Southern District of California, accuses Aardvark of failing to adequately inform investors about the safety issues surrounding its drug ARD-101. Allegations state that Aardvark misrepresented the clinical and commercial prospects of ARD-101, leading to significant share price depreciation.

The situation worsened on February 27, 2026, when Aardvark announced a voluntary pause in the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial due to concerns arising from routine safety monitoring. Following this announcement, Aardvark's share price plummeted by $7.02 per share, signifying a dramatic 56.2% decline within a span of days, closing at $5.47 per share on March 2, 2026.

Important Timeline and Deadlines

Investors who acquired shares during the aforementioned class period and experienced losses should be aware that the lead plaintiff deadline is set for October 13, 2026. This critical date will determine who can step forward as the principal investigator in representing the collective interests of the affected shareholders.

Why Choose Wolf Haldenstein?

Founded in 1888, Wolf Haldenstein has established itself as a prominent defender of the rights of investors. With over 125 years of legal experience, the firm remains committed to seeking justice for those affected by misleading corporate disclosures. Potential plaintiffs can reach out to the firm without any cost or obligation to explore their options regarding the lawsuit.

For those who believe they may qualify, the firm encourages contacting their offices. Chief among the points of contact is Gregory Stone, the director overseeing case and financial analysis. Interested parties can call (800) 575-0735 or (212) 545-4774, or reach out via email at [email protected].

Conclusion

As the class action against Aardvark Therapeutics advances, shareholders who have suffered losses must take action promptly. With Wolf Haldenstein leading the charge, affected investors now have a fighting chance to reclaim their financial well-being through legal recourse. Stay tuned for further updates on this developing case.